OREXIGEN THERAPEUTICS, INC.

• SAN DIEGO, CA
Create Email Alert

Orexigen Therapeutics is based out of San Diego. Orexigen Therapeutics, Inc. operates as a biopharmaceutical company focusing on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. Its lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II development. These two product candidates are designed based on the company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.Whalewisdom has at least 211 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2017-03-03. The notice included securities offered of Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Contact Info

orexigen therapeutics, inc.
12481 HIGH BLUFF DRIVE, SUITE 160
SAN DIEGO CA    92130
Business Phone: (858) 436-8600
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2017-03-03 D PHARMACEUTICALS Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 49,597,000 49,597,000 0
2016-03-29 D PHARMACEUTICALS Equity,Debt,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 329,999,991 165,000,000 164,999,991
2015-09-15 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 90,000,000 60,000,000 30,000,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
MICHAEL NARACHI subscription required
    EXECUTIVE OFFICER DIRECTOR
JOSEPH HAGAN subscription required
    EXECUTIVE OFFICER
THOMAS CANNELL subscription required
    EXECUTIVE OFFICER
PRESTON KLASSEN subscription required
    EXECUTIVE OFFICER
LOUIS C BOCK subscription required
    DIRECTOR
WENDY L DIXON subscription required
    DIRECTOR
BRIAN H. DOVEY subscription required
    DIRECTOR
DAVID J ENDICOTT subscription required
    DIRECTOR
PETER K HONIG subscription required
    DIRECTOR
PATRICK J MAHAFFY subscription required
    DIRECTOR
LOTA S ZOTH subscription required
    DIRECTOR
ECKARD WEBER subscription required
    DIRECTOR
THOMAS LYNCH subscription required
    EXECUTIVE OFFICER
HEATHER ACE subscription required
    EXECUTIVE OFFICER
PETER FLYNN subscription required
    EXECUTIVE OFFICER
DEBORAH JORN subscription required
    DIRECTOR
JASON KEYES subscription required
    EXECUTIVE OFFICER

Elevate your investments